keyword
MENU ▼
Read by QxMD icon Read
search

Treatment-resistant Schizophrenia

keyword
https://www.readbyqxmd.com/read/28225745/predictors-of-nonhospitalization-and-functional-response-in-clozapine-treatment-a-nationwide-population-based-cohort-study
#1
Ole Köhler-Forsberg, Henriette T Horsdal, Sophie E Legge, James H MacCabe, Christiane Gasse
BACKGROUND: Clozapine remains the only evidence-based treatment for treatment-resistant schizophrenia, and prediction of clozapine response is important in developing stratified treatment. We studied potential predictors of clozapine response, applying functional assessments as well as service use. PROCEDURES: We performed a nationwide cohort study among all individuals diagnosed with schizophrenia in Denmark after 1995 (age, ≥18 years) who initiated clozapine treatment between 2004 and 2011 with a Global Assessment of Functioning (GAF-F) score registered at clozapine initiation...
April 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28184875/polygenic-risk-score-for-schizophrenia-and-treatment-resistant-schizophrenia
#2
Theresa Wimberley, Christiane Gasse, Sandra Melanie Meier, Esben Agerbo, James H MacCabe, Henriette Thisted Horsdal
No abstract text is available yet for this article.
February 10, 2017: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/28163559/new-schizophrenia-treatments-address-unmet-clinical-needs
#3
Chris Fellner
We present several novel drugs in development for enhancing cognition, treating negative symptoms, and providing improved options for treatment-resistant patients. Drug makers aim to enhance safety profiles and increase patient compliance to therapy.
February 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28162976/neuromodulation-in-response-to-electroconvulsive-therapy-in-schizophrenia-and-major-depression
#4
Philipp Arthur Thomann, Robert Christian Wolf, Henrike Maria Nolte, Dusan Hirjak, Stefan Hofer, Ulrich Seidl, Malte Sebastian Depping, Bram Stieltjes, Klaus Maier-Hein, Fabio Sambataro, Torsten Wüstenberg
BACKGROUND: Electroconvulsive therapy (ECT) is one of the most effective treatments in severe and treatment-resistant major depressive disorder (MDD). ECT has been also shown to be effective in schizophrenia (SZ), particularly when rapid symptom reduction is needed or in cases of resistance to drug-treatment. However, its precise mechanisms of action remain largely unknown. OBJECTIVE/HYPOTHESIS: This study examined whether ECT exerts disorder-specific or unspecific modulation of brain structure and function in SZ and MDD...
January 16, 2017: Brain Stimulation
https://www.readbyqxmd.com/read/28153339/characterization-of-admission-types-in-medically-hospitalized-patients-prescribed-clozapine
#5
Jonathan G Leung, M Earth Hasassri, Jason N Barreto, Sarah Nelson, Robert J Morgan
BACKGROUND: Clozapine is the antipsychotic of choice for treatment-resistant schizophrenia; however, rigorous monitoring is required to prevent or detect adverse drug events that contribute to morbidity and mortality. In addition to the Food and Drug Administration (FDA) boxed safety warnings specific to clozapine (agranulocytosis, hypotension, seizures, and cardiomyopathy/myocarditis), other adverse events such as pneumonia and gastrointestinal hypomotility have been reported in the literature to result in hospitalization...
November 18, 2016: Psychosomatics
https://www.readbyqxmd.com/read/28152470/effectiveness-of-electroconvulsive-therapy-in-patients-with-treatment-resistant-schizophrenia-a-retrospective-study
#6
Sandeep Grover, Subho Chakrabarti, Nandita Hazari, Ajit Avasthi
This study aimed to evaluate the effectiveness of electroconvulsive therapy (ECT) among patients with treatment resistant schizophrenia (TRS). Records of patients who had received ECT were reviewed to identify patients with TRS who were administered ECT in combination with clozapine. Socio-demographic, clinical data and ECT details were extracted. The most common diagnosis was of paranoid schizophrenia (49%) followed by undifferentiated schizophrenia (36%). A-fifth (22%) of the patients were judged to have poor response to clozapine...
January 18, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28142068/the-critical-treatment-window-of-clozapine-in-treatment-resistant-schizophrenia-secondary-analysis-of-an-observational-study
#7
Bunta Yoshimura, Yuji Yada, Ryuhei So, Manabu Takaki, Norihito Yamada
Previous studies have suggested that a delay in initiating clozapine is one of the predictors of outcomes in treatment-resistant schizophrenia (TRS). However, whether there is a critical treatment window of clozapine in TRS and the duration of that window remain unclear. We conducted a secondary analysis of a previously published observational study using a retrospective chart review of 105 patients with TRS who were treated with clozapine. We included 90 patients who remained on clozapine for at least 3 months...
January 24, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28141630/neuroprotective-effect-of-modified-electroconvulsive-therapy-for-schizophrenia-a-proton-magnetic-resonance-spectroscopy-study
#8
Jing-Li Gan, Hui-Feng Duan, Zheng-Xiang Cheng, Jia-Ming Yang, Xi-Quan Zhu, Cun-You Gao, Lan-Min Zhao, Xue-Jun Liang
The underlying mechanism of modified electroconvulsive therapy (MECT) treatment for drug-resistant and catatonic schizophrenia remains unclear. Here, we aim to investigate whether MECT exerts its antipsychotic effects through elevating N-acetylaspartate (NAA) concentration measured by proton magnetic resonance spectroscopy (H-MRS). Multiple-voxel H-MRS was acquired in the bilateral prefrontal cortex (PFC) and thalamus to obtain measures of neurochemistry in 32 MECT, 34 atypical antipsychotic-treated schizophrenic patients, and 34 healthy controls...
January 30, 2017: Journal of Nervous and Mental Disease
https://www.readbyqxmd.com/read/28138403/clozapine-in-a-patient-with-treatment-resistant-schizophrenia-and-hypertrophic-cardiomyopathy-a-case-report
#9
Asiel Yair Adan Sanchez, Jessica J Foster, Carla M Plymen, Sukhi Shergill
BACKGROUND: There is currently limited experience in the initiation and maintenance of clozapine for treatment-resistant psychosis in adults with established structural heart disease. These complex patients require close supervision and liaison between colleagues. Here we present the successful experience of treating one such patient within our service and describe a monitoring plan to ensure that these treatments can be provided both safely and effectively. CASE PRESENTATION: A 36-year-old man with treatment-resistant schizophrenia and known hypertrophic cardiomyopathy (HCM) was admitted to a specialist unit for a trial of clozapine...
November 2016: BJPsych Open
https://www.readbyqxmd.com/read/28128334/protein-kinase-c-%C3%AE-a-new-target-therapy-to-prevent-the-long-term-atypical-antipsychotics-induced-weight-gain
#10
Alessandro Rimessi, Chiara Pavan, Elli Ioannidi, Federica Nigro, Claudia Morganti, Alberto Brugnoli, Francesco Longo, Chiara Gardin, Letizia Ferroni, Michele Morari, Vincenzo Vindigni, Barbara Zavan, Paolo Pinton
Antipsychotic drugs are currently used in clinical practice for a variety of mental disorders. Among them, clozapine is the most effective medication for treatment-resistant schizophrenia and is most helpful in controlling aggression and the suicidal behavior in schizophrenia and schizoaffective disorder. Although clozapine is associated with a low likelihood of extrapyramidal symptoms and other neurological side effects, it is well-known for the weight gain and metabolic side effects, which expose the patient to a greater risk of cardiovascular disorders, premature death, as well as psychosocial issues leading to non-adherence to therapy...
January 27, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28109666/diminished-auditory-sensory-gating-during-active-auditory-verbal-hallucinations
#11
Robert J Thoma, Andrew Meier, Jon Houck, Vincent P Clark, Jeffrey D Lewine, Jessica Turner, Vince Calhoun, Julia Stephen
Auditory sensory gating, assessed in a paired-click paradigm, indicates the extent to which incoming stimuli are filtered, or "gated", in auditory cortex. Gating is typically computed as the ratio of the peak amplitude of the event related potential (ERP) to a second click (S2) divided by the peak amplitude of the ERP to a first click (S1). Higher gating ratios are purportedly indicative of incomplete suppression of S2 and considered to represent sensory processing dysfunction. In schizophrenia, hallucination severity is positively correlated with gating ratios, and it was hypothesized that a failure of sensory control processes early in auditory sensation (gating) may represent a larger system failure within the auditory data stream; resulting in auditory verbal hallucinations (AVH)...
January 18, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28104562/assessing-patient-rated-vs-clinician-rated-adherence-to-the-therapy-in-treatment-resistant-schizophrenia-schizophrenia-responders-and-non-schizophrenia-patients
#12
Felice Iasevoli, Andrea Fagiolini, Maria Vittoria Formato, Emiliano Prinzivalli, Sara Giordano, Raffaele Balletta, Vincenzo De Luca, Andrea de Bartolomeis
The present study evaluated consistency, reliability, and determinants of two real-world measures of adherence to prescription in 57 schizophrenia and 61 non-schizophrenia patients. Treatment resistant schizophrenia (TRS) was additionally diagnosed in 28 of the schizophrenia patients. Patients were screened for clinical severity, cognitive functioning, and adherence by 10-item Drug Attitude Inventory (DAI-10) or Adherence-to-Therapy (AtT), a clinician-rated tool developed by our group. DAI-10 and AtT scores showed a significant correlation (p=0...
January 7, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28097367/impaired-glucose-homeostasis-in-first-episode-schizophrenia-a-systematic-review-and-meta-analysis
#13
Toby Pillinger, Katherine Beck, Cristian Gobjila, Jacek G Donocik, Sameer Jauhar, Oliver D Howes
Importance: Schizophrenia is associated with an increased risk of type 2 diabetes. However, it is not clear whether schizophrenia confers an inherent risk for glucose dysregulation in the absence of the effects of chronic illness and long-term treatment. Objective: To conduct a meta-analysis examining whether individuals with first-episode schizophrenia already exhibit alterations in glucose homeostasis compared with controls. Data Sources: The EMBASE, MEDLINE, and PsycINFO databases were systematically searched for studies examining measures of glucose homeostasis in antipsychotic-naive individuals with first-episode schizophrenia compared with individuals serving as controls...
January 11, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28094812/putative-presynaptic-dopamine-dysregulation-in-schizophrenia-is-supported-by-molecular-evidence-from-post-mortem-human-midbrain
#14
T D Purves-Tyson, S J Owens, D A Rothmond, G M Halliday, K L Double, J Stevens, T McCrossin, C Shannon Weickert
The dopamine hypothesis of schizophrenia posits that increased subcortical dopamine underpins psychosis. In vivo imaging studies indicate an increased presynaptic dopamine synthesis capacity in striatal terminals and cell bodies in the midbrain in schizophrenia; however, measures of the dopamine-synthesising enzyme, tyrosine hydroxylase (TH), have not identified consistent changes. We hypothesise that dopamine dysregulation in schizophrenia could result from changes in expression of dopamine synthesis enzymes, receptors, transporters or catabolic enzymes...
January 17, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28086761/is-treatment-resistant-schizophrenia-categorically-distinct-from-treatment-responsive-schizophrenia-a-systematic-review
#15
Amy L Gillespie, Ruta Samanaite, Jonathan Mill, Alice Egerton, James H MacCabe
BACKGROUND: Schizophrenia is a highly heterogeneous disorder, and around a third of patients are treatment-resistant. The only evidence-based treatment for these patients is clozapine, an atypical antipsychotic with relatively weak dopamine antagonism. It is plausible that varying degrees of response to antipsychotics reflect categorically distinct illness subtypes, which would have significant implications for research and clinical practice. If these subtypes could be distinguished at illness onset, this could represent a first step towards personalised medicine in psychiatry...
January 13, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28071142/erratum
#16
(no author information available yet)
Lee J, Takeuchi H, Fervaha G, Sin GL, Foussias G, Agid O, Farooq S, Remington G. Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms. Can J Psychiatry. 2015;60(11):515-522. Original DOI: 10.1177/070674371506001107. In Table 2 of the above article, in "Proposed criteria for clozapine resistance" for "Current illness severity," the CGI-SCH positive was stated as "> 4" but it should be "CGI-SCH positive ≥ 4." The corrected table is below. [Table: see text]...
March 2016: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/28067751/efficacy-of-clozapine-on-dopamine-supersensitivity-psychosis-in-schizophrenia
#17
Yusuke Nakata, Nobuhisa Kanahara, Hiroshi Kimura, Hiroyuki Watanabe, Masaomi Iyo
Although the effectiveness of clozapine (CLZ) for patients with treatment-resistant schizophrenia (TRS) has been well established, its active mechanism has not been completely clarified. Several clinical studies showed that neuroleptic-induced dopamine supersensitivity psychosis (DSP) could be involved in the etiology of TRS. We preliminarily explored the possible beneficial effect of CLZ for dopamine supersensitivity schizophrenia. The present study is a case series. We followed 15 patients with DSP for about 2...
January 6, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28064233/clozapine-associated-with-autoimmune-reaction-fever-and-low-level-cardiotoxicity-a-case-report
#18
Charilaos Gerasimou, Georgia Phaedra Vitali, George D Vavougios, Charalabos Papageorgiou, Athanasios Douzenis, Styliani I Kokoris, Ioannis Liappas, Emmanouil Rizos
BACKGROUND: Clozapine is a second-generation antipsychotic drug used in treatment-resistant schizophrenia. Fever induced by clozapine is a rather frequent side-effect which usually occurs in the first 4 weeks of treatment. Despite its effectiveness, there are potentially life-threatening adverse effects, such as cardiotoxicity. CASE REPORT: We present the case of a 31-year-old caucasian male with refractory schizophrenia who developed benign fever, increase of C-reactive protein and high troponin levels, without presenting any other signs to myocarditis, on the 13th day under clozapine treatment, which declined progressively upon discontinuation of the drug...
January 2017: In Vivo
https://www.readbyqxmd.com/read/28062471/pharmacological-guidelines-for-schizophrenia-a-systematic-review-and-comparison-of-recommendations-for-the-first-episode
#19
Dolores Keating, Stephen McWilliams, Ian Schneider, Caroline Hynes, Gráinne Cousins, Judith Strawbridge, Mary Clarke
OBJECTIVES: Clinical practice guidelines (CPGs) support the translation of research evidence into clinical practice. Key health questions in CPGs ensure that recommendations will be applicable to the clinical context in which the guideline is used. The objectives of this study were to identify CPGs for the pharmacological treatment of first-episode schizophrenia; assess the quality of these guidelines using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument; and compare recommendations in relation to the key health questions that are relevant to the pharmacological treatment of first-episode schizophrenia...
January 6, 2017: BMJ Open
https://www.readbyqxmd.com/read/28017493/music-evoked-emotions-in-schizophrenia
#20
Daijyu Abe, Makoto Arai, Masanari Itokawa
BACKGROUND/OBJECTIVES: Previous studies have reported that people with schizophrenia have impaired musical abilities. Here we developed a simple music-based assay to assess patient's ability to associate a minor chord with sadness. We further characterize correlations between impaired musical responses and psychiatric symptoms. METHOD: We exposed participants sequentially to two sets of sound stimuli, first a C-major progression and chord, and second a C-minor progression and chord...
December 23, 2016: Schizophrenia Research
keyword
keyword
7312
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"